Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Breast cancer is a multifactorial disease affecting women, and one of the treatments for its healing and survival is hormone therapy. Aromatase inhibitors are third-generation drugs that promote lower chance of metastasis, but their side effects include the loss of bone mineral density and increased fat percentage. In this way, the Combined Training (combined resistance and endurance training) may be an interesting strategy to minimize the side effects of aromatase inhibitors, providing better quality of life, survival and changes in body composition.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group Control with breast cancer and without breast cancer | No Intervention | Stretching exercises, lasting 40 minutes each session, 2 times a week for nine months | |
| Combined Training with breast cancer and without breast cancer | Experimental | Combined Training: 36 weeks duration, 3 times a week on nonconsecutive days. The combined training program lasts 70 minutes per session, with 40 minutes of resistance training and 30 minutes of aerobic training. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Combined Training | Behavioral |
|
| Measure | Description | Time Frame |
|---|---|---|
| Chance from Body composition at 9 months assessment by bone densitometry (Dual-energy x-ray absorptiometry), using the equipment model GE Lunar - DPX-NT | At baseline, 3, 6 and 9 months timepoint |
| Measure | Description | Time Frame |
|---|---|---|
| Quality of life assessed via the questionnaire EORTC (European Organization for Research and Treatment of Cancer Quality of Life Questionnarie). | At baseline, 3, 6 and 9 months timepoint | |
| Bone mineral density (total, spine and femur) in these participants by bone densitometry (Dual-energy x-ray absorptiometry), using the equipment model GE Lunar - DPX-NT. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ismael F Freitas Junior, Doctor | UPECLIN HC FM Botucatu Unesp | Study Director |
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 32375779 | Derived | Felipe J, Viezel J, Reis AD, da Costa Barros EA, de Paulo TRS, Neves LM, Junior IFF. Relationship of different intensities of physical activity and quality of life in postmenopausal women. Health Qual Life Outcomes. 2020 May 6;18(1):123. doi: 10.1186/s12955-020-01377-1. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| At baseline, 3, 6 and 9 months timepoint |
| Serum levels of glucose in these participants measured by enzymatic colorimetric kit processed in Autohumalyzer A5 | At baseline, 3, 6 and 9 months timepoint |
| Serum levels of C-reactive protein (CRP) in these participants measured by enzymatic colorimetric kit processed in Autohumalyzer A5 | At baseline, 3, 6 and 9 months timepoint |
| Serum levels of total cholesterol and fractions in these participants measured by enzymatic colorimetric kit processed in Autohumalyzer A5. | At baseline, 3, 6 and 9 months timepoint |
| Serum levels of triacylglycerol in these participants measured by enzymatic colorimetric kit processed in Autohumalyzer A5 | At baseline, 3, 6 and 9 months timepoint |
| Serum of osteocalcin and the carboxyterminal telopeptides of collagen type I (CTX) measured at Serum CrossLaps Assay | At baseline, 3, 6 and 9 months timepoint |
| Physical Activity of accelerometer motion sensor type triaxial Actigraph brand, mode GT3X. | At baseline, 3, 6 and 9 months timepoint |
| The perception of pain is measured by Pain Brief Questionnaire (PBQ | At baseline, 3, 6 and 9 months timepoint |
| VO2max by test of submaximal effort | At baseline, 3, 6 and 9 months timepoint |
| Responsiveness on body composition by bone densitometry (Dual-energy x-ray absorptiometry). | At baseline, 3 and 6 months timepoint |
| Responsiveness on habitual physical activity by accelerometer motion sensor type triaxial Actigraph brand, mode GT3X (Actigraph LLC, Pensacola, FL). | At baseline, 3 and 6 months timepoint |
| Use time of aromatase inhibitor and the response to combined training in the variables of body composition and level of physical activity by bone densitometry (GE Lunar - DPX-NT) and accelerometer motion sensor type triaxial Actigraph brand, mode GT3X | At baseline, 3 and 6 months timepoint |
| Self reported Drug consumption questionnaire | At baseline, 3, 6 and 9 months timepoint |
| D017437 |
| Skin and Connective Tissue Diseases |